SB 977 adds a new chapter to Title 1 of the U.S. Code that forbids the expenditure of any funds authorized or appropriated by federal law for “gender transition procedures,” and bars federal funds from paying for health benefits plans that include such procedures. The bill also prohibits federal facilities and federal employees from providing those procedures and creates narrow exceptions for disorders of sex development, treatment of complications, precocious puberty, and male circumcision.
The bill reaches beyond direct federal provision: it amends the tax code to deny premium tax credits and cost‑sharing reductions for qualified health plans that include coverage for these procedures, disqualifies plans from the small employer health insurance credit, and directs multi‑state plan contracts to comport with the new federal prohibition. It permits separate, wholly non‑federally funded coverage so long as no federal funds or matching funds (including Medicaid match) are used to buy that coverage.
Compliance, program administration, and coverage gaps are the immediate operational issues for federal programs, States, insurers, and providers.
At a Glance
What It Does
The bill adds a new Chapter 4 to Title 1 that (1) bars any federal funds or federal trust funds from paying for gender‑transition procedures or health plans covering them, (2) prevents federal facilities and federal employees from providing those procedures, and (3) allows separate private coverage paid entirely with non‑federal funds. It amends the Internal Revenue Code to make plans that cover these procedures ineligible for premium tax credits, cost‑sharing reductions, and the small employer credit.
Who It Affects
Federal programs and trust funds (Medicaid, Medicare, VA, TRICARE, FEHB, and other federally supported coverage), federally operated health facilities and personnel, health insurers that sell ACA‑compliant plans or seek federal subsidies, States that rely on Medicaid match, and individuals seeking gender‑affirming care.
Why It Matters
The bill shifts coverage decisions from federal sponsorship to private or state funding streams, removing federal subsidies and creating new compliance rules for tax credits and multi‑State plans. That combination changes who pays, which plans qualify for federal support, and how federal programs administer claims and matching funds.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 977 creates a standalone federal prohibition on using any federal dollars—whether direct appropriations or money in federal trust funds—to pay for “gender transition procedures,” a broadly defined category that includes a long list of hormonal and surgical interventions. The ban extends to federal health benefits coverage: if a plan includes those procedures, federal funds may not be expended for that plan.
The bill also bars federal health facilities and federally employed clinicians from furnishing such procedures while carving out a set of specific exceptions.
To implement the prohibition inside the Affordable Care Act framework, the bill amends the Internal Revenue Code so that premium tax credits and cost‑sharing reductions cannot be used for qualified health plans that include coverage of gender transition procedures. It likewise excludes such plans from eligibility for the small employer health insurance credit and requires multi‑State plan contracts to conform to the federal prohibition.
Importantly, the bill permits insurers or individuals to purchase separate policies or riders that cover these procedures, but only if those policies are paid for entirely with non‑federal funds and not purchased using Medicaid matching funds or federal premium subsidy dollars.The definitions section is central to enforcement: it supplies a working definition of “gender transition” and enumerates what qualifies as a “gender transition procedure,” naming both classes of interventions (puberty blockers, cross‑sex hormones) and dozens of specific surgeries and cosmetic procedures. The text also includes exclusions for people born with medically verifiable disorders of sex development, treatments for complications caused by a gender‑transition procedure, puberty suppression for precocious puberty, and routine male circumcision.
Those exclusions will shape how claims are reviewed and when federal dollars may still be used for particular services.For administrators and insurers, the bill creates new operational requirements: plan certification must demonstrate that federal funds are not used for the covered items, tax‑credit calculations must exclude plans (or portions of premiums) covering the enumerated services, and States must ensure that any state‑funded coverage that includes these procedures does not rely on federal matching dollars. The effective timing for the tax and plan changes is phased: the tax amendments apply to taxable years ending after one year from enactment and only with respect to plan years beginning after that date; the multi‑State plan amendment applies to plan years beginning after that date as well.Taken together, the bill replaces federal sponsorship of a set of gender‑affirming services with a regime that permits private payment or state action but withdraws federal subsidy, reimbursement, and provision.
That creates immediate administrative questions about claiming, billing, plan design, and the boundary between federally permitted treatment (e.g., complications, DSD care) and the barred procedures themselves.
The Five Things You Need to Know
The bill’s funding ban applies to “any funds authorized or appropriated by Federal law” and explicitly includes funds held in federal trust funds.
The statutory definition lists hormonal interventions (GnRH agonists, supraphysiologic testosterone/estrogen) and an extensive catalog of surgeries and cosmetic procedures, plus language covering the removal of otherwise healthy, non‑diseased body parts.
States, insurers, or individuals may buy separate coverage for gender transition procedures only if paid entirely with non‑federal funds and not with Medicaid matching funds or premium tax credits.
Section 201 amends IRC section 36B and section 45R to disallow premium tax credits, cost‑sharing reductions, and the small employer credit for plans that include coverage for the listed procedures, and permits only separate unsubsidized coverage as an option.
The bill exempts care for medically verifiable disorders of sex development, treatment of complications caused or exacerbated by a gender‑transition procedure, precocious‑puberty suppression, and male circumcision from the federal funding ban.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Broad prohibition on federal funding for gender‑transition procedures
Section 301 bars expenditure of any federal funds—including amounts in federal trust funds—for any gender‑transition procedure. Practically, that prevents federal programs from directly paying for those interventions and establishes the baseline funding restriction that the rest of the chapter and Title II operationalize.
Prohibition on federal funding for health plans that cover these procedures
Section 302 extends the funding bar to health benefits coverage: if a health plan covers gender‑transition procedures, federal funds may not be expended for that plan. This provision targets federally supported plan dollars and creates a compliance requirement for any insurer participating in federally subsidized markets or plans with federal funding.
Federal facility and treatment carve‑outs, and non‑federal coverage paths
Section 303 prevents federal facilities and federally employed clinicians from furnishing gender‑transition procedures. Sections 304–305 allow private parties, States, or entities to buy separate coverage for these procedures—but only with non‑federal funds and not using federally required Medicaid match. Section 306 clarifies that federal funds still may be used to treat infections, injuries, diseases, or disorders caused or worsened by such procedures. These mechanics create a bifurcated approach: direct federal provision is barred while private, unsubsidized paths remain possible, and treatment of complications is not blocked.
Definitions that drive scope and exclusions
Section 307 supplies operational definitions—defining male, female, sex, gender transition, and a long list of ‘gender transition procedures,’ from puberty blockers and cross‑sex hormones to dozens of named surgical and cosmetic interventions. The definition also contains specific exclusions for disorders of sex development (DSD), medically necessary care for complications, precocious puberty treatment, and male circumcision. Enforcement hinges on these definitions, and many operational questions—medical necessity, what counts as a complication, and how to evaluate hormone dosing—flow from this section.
Tax code changes to remove federal subsidies and multi‑State plan conformity
Title II amends IRC §36B to make premium tax credits and cost‑sharing reductions unavailable for qualified health plans that include coverage for gender‑transition procedures and inserts permissive language allowing separate, unsubsidized coverage. It amends §45R to exclude such plans from the small employer credit and adds a requirement that multi‑State plans conform to the federal policy. The amendments include an effective timing rule tied to taxable years ending after one year from enactment and to subsequent plan years, creating a phased implementation for subsidy and plan‑design changes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Insurers and issuers that choose to offer separate, unsubsidized riders or standalone policies covering gender‑transition procedures: they can continue to sell such coverage so long as premiums are funded entirely by non‑federal sources.
- Employers that do not want to cover gender‑transition procedures: by ensuring plans excluding these procedures remain eligible for federal subsidies, they face fewer regulatory or subsidy pressures to include the services.
- States and localities that prefer to control coverage via state funds: the bill lets States design and pay for coverage without federal participation, preserving state discretion for those willing to allocate non‑federal dollars.
- Federal budget administrators: removing an explicit federal funding pathway reduces potential federal outlays for these procedures and centralizes the decision about who pays outside the federal purse.
- Insurers and plan administrators in federally subsidized markets: the ban creates a clearer compliance standard for what can be certified as a federally supported qualified health plan (no ambiguous carve‑ins that trigger subsidy ineligibility).
Who Bears the Cost
- Individuals seeking gender‑affirming interventions who previously relied on federal programs or subsidies to pay for care: they will need to secure non‑federal funding or state support where available.
- State Medicaid programs that previously used federal matching funds to cover such services or that may face pressure to fund them without federal match: the bill prohibits using Medicaid match to purchase separate coverage for these procedures.
- Health insurers and multi‑State plan issuers that included gender‑affirming services in ACA plans: they lose eligibility for premium tax credits and the small employer credit unless they segregate coverage into unsubsidized products.
- Federal health programs and agencies (Medicare, VA, TRICARE, FEHB): they must update coverage rules, claims processing, provider contracts, and potentially reassign or retrain staff to implement the prohibition.
- Providers who perform these procedures and rely on federal reimbursement streams: they may see reduced demand from federally insured patients and face administrative complexity when billing separately funded coverage versus federally funded coverage.
Key Issues
The Core Tension
The central trade‑off is between Congress’s aim to stop federal sponsorship of a set of medical interventions and the administrative, clinical, and access consequences of withdrawing that sponsorship: banning federal funding simplifies a federal policy stance but shifts costs, complexity, and clinical decisionmaking to states, insurers, providers, and patients—often creating difficult line‑drawing problems about medical necessity, diagnosis, and the permissible use of federal versus non‑federal funds.
The bill’s practical effect depends on disputed and administratively difficult lines. First, the definition of “gender transition procedure” is expansive and mixes clearly defined interventions (e.g., hysterectomy, orchiectomy) with medically contingent terms (e.g., “supraphysiologic” dosing).
Regulators will need to translate those terms into clinical thresholds for claims processing; absent agency guidance, payors and providers will face inconsistent adjudication. Second, the carve‑outs for disorders of sex development and treatment of complications create inevitable factual inquiries: determining whether a procedure was for a DSD, a complication, or part of an excluded medical necessity pathway invites record‑level review and potential disputes over coding and documentation.
Third, the bill’s mechanism that permits separate, non‑federal coverage but forbids use of Medicaid matching funds or premium tax credits raises complex accounting and market‑design issues. Insurers will need robust mechanisms to segregate premiums, riders, and claims so that tax‑credit‑eligible dollars do not subsidize excluded services.
States that wish to maintain coverage using their own funds must ensure those dollars are not commingled with federal match—a burdensome compliance task. Finally, the intersection with other federal legal obligations (for example, nondiscrimination provisions in federal health programs or ERISA plan rules for employer‑sponsored coverage) is unresolved in the text and is likely to produce litigation and administrative disputes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.